MedTrace Logo

Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)

NCT00279565 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2012-11-22

No results posted yet for this study

Summary

This randomized, single-center, controlled study is designed to evaluate the safety, tolerability, and efficacy of treatment with Peg-Intron with Rebetol in methadone or buprenorphine maintenance patients with hepatitis C.

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

buprenorphine

DRUG

methadone

DRUG

pegylated interferon alfa-2b plus ribavirin

Sponsors & Collaborators

  • AESCA Pharma GmbH

    collaborator INDUSTRY

  • Indivior Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2007-02-28
Completion
2007-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00279565 on ClinicalTrials.gov